SIHUAN PHARM (00460): Innovative drug Anjuwei successfully renewed and included in the 2025 National Basic Medical Insurance Drug List.

SIHUAN PHARM (00460) announced that following a simplified medical insurance renewal with the National Medical Insurance Bureau, the innovative drug Anweira Sodium Enteric-coated Tablet (trade name: Anjiuwei) independently developed by its non-wholly-owned subsidiary Xuanzhu Bio-Technology Co., Ltd. will continue to be included in the new edition of the National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List (2025) (2025 National Basic Medical Insurance Drug List) effective from January 1, 2026. As the first and only domestically developed proton pump inhibitor, Anjiuwei was approved for market in China in June 2023 for the treatment of duodenal ulcers, and was first included in the National Basic Medical Insurance Drug List in December 2023. The successful renewal of Anjiuwei in the 2025 National Basic Medical Insurance Drug List will benefit the stability of market sales, continue to benefit more patient populations, improve the product's penetration rate in relevant indications, and inject momentum into the long-term growth of Anjiuwei.